BC Platforms extends precision medicine partnership with Bumrungrad

The partnership aims to accelerate precision medicine adoption in SEA.

Healthcare data management and analytics company BC Platforms announced the extension of its partnership with Thailand's Bumrungrad International Hospital on 20 October.

First formed in 2019, BC Platforms partnered with the hospital to build on clinical sample management functionalities and existing automated workflows for genotype-based wellness reporting and next-generation sequencing (NGS) neonatal screening. Presently, Bumrungrad will utilise BCP's BC|GENOME to implement end-to-end clinical NGS workflows for germline and somatic tumour testing, enabling data-driven personalised care for patients. Additionally, BCP will provide BC|INSIGHT for curating and analysing clinical and omics data in a secure format to enhance translational research capabilities at Bumrungrad and boost research collaborations.

Bumrungrad research and development director Teeradache Viangteeravat commented, "We require a big data platform to support sample management, data processing, informatics pipelines, reporting and structured storage. BC Platforms is a world leader in this space and can provide a suite of integrated solutions, which support our strategic objectives and also support searching of genotypic and phenotypic data, for collaborative research projects."

BCP deputy managing director Nino da Silva added, "We are delighted to expand our partnership with Bumrungrad, making full use of our platforms to accelerate the shift towards precision medicine in southeast Asia. This powerful NGS infrastructure will deliver whole-genome analysis to Bumrungrad's clinical healthcare production system while supporting advanced clinical research."

Bumrungrad will also become a BCP data partner, for which it will contribute valuable, diverse data samples for research.